Ibipinabant (SLV319) is a potent, selective and orally active antagonist of cannabinoid CB1 receptor , with a K i of 7.8 nM. Ibipinabant shows more than 1000-fold selectivity for CB1 over CB2 (K i =7943 nM). Ibipinabant can be used for the research of obesity and diabetic.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Cannabinoid Receptor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.